Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity

DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the human ovarian cancer cell line A2780 for resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Hattum, A H, Hoogsteen, I J, Schlüper, H M M, Maliepaard, M, Scheffer, G L, Scheper, R J, Kohlhagen, G, Pommier, Y, Pinedo, H M, Boven, E
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2002
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364245/
https://ncbi.nlm.nih.gov/pubmed/12237778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600508
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados